To provide the information your oncologist is not telling you or doesn't have the time to!
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
Multiple myeloma (MM) is a type of blood cancer that originates in the plasma cells, which are a type of white blood cell found in the bone marrow. Plasma cells are responsible for producing antibodies that help fight infections. In multiple myeloma, abnormal plasma cells multiply uncontrollably, leading to a range of complications. Key Characteristics …
When it comes to battling a rare and aggressive cancer like synovial sarcoma, the treatment options have often been limited—until now. The FDA’s recent approval of Tecelra (Amafi-Cel), the first gene therapy for adults with metastatic synovial sarcoma, not only provides new hope for patients who’ve exhausted other options but also paves the way for …
Deciding to join a clinical trial can feel daunting, especially with the myths and misconceptions that surround them. Let’s take a moment to clear the air and set the record straight about what clinical trials really mean for you as a patient. Myth #1: “I’m Just a Lab Rat” Contrary to popular belief, participating in …
The American Society of Clinical Oncology (ASCO) 2024 conference was a remarkable event, bringing together leading minds in oncology to discuss the latest breakthroughs and research in cancer treatment. This year’s conference was particularly notable for the innovative approaches presented in the treatment of metastatic melanoma, a challenging and aggressive form of skin cancer. In …
New article published in NEJM demonstrated activity of Pembrolizumab adjuvantly given for resected intermediate, poor risk and resected metastatic RCC. Kidney cancer remains a significant health challenge worldwide, with renal-cell carcinoma (RCC) being the most common type. Traditionally, surgery has been the primary treatment for localized kidney cancer, but the risk of recurrence remains high. …
New exciting data published in the NEJM demonstrating improved for a specific subset of lung cancer patients but also demonstrating the power of targeted therapies when we can identify a driver mutation that is sensitive or “actionable” with a treatment to shut down its specific function. Exciting! Non-Small Cell Lung Cancer (NSCLC) represents a significant …
The medical community continues to explore groundbreaking treatments in the fight against cancer, with CAR-T therapy standing out for its innovative approach. This treatment, involving the genetic modification of a patient’s T cells to target cancer cells, has provided new avenues for those battling certain blood cancers. Here, we delve into the essence of CAR-T …
Last week, we heard the tremendous news regarding the FDA approval of Lifileucel for metastatic melanoma refractory to prior immunotherapy checkpoint inhibitor therapy. In this article, let’s focus on an uncommon melanoma subtype in the general population that we routinely see in practice. In the realm of oncology, the fight against cancer continually evolves, marked …
On February 16th 2024, after a roughly 2-3 year wait fully aware of the data and the patient beneficial long term outcomes in a subset of patients, the FDA finally announced the approval of the first cellular therapy approved for solid tumors and specifically TIL in treatment refractory malignant melanoma. TIL using Amtagvi (Lifileucel) is …
The journey of understanding and treating metastatic bladder cancer has been marked by both challenges and triumphs. This cancer, which starts in the lining of the bladder and spreads beyond, represents a critical area in oncology due to its high incidence and aggressive nature. As per the latest statistics, metastatic bladder cancer accounts for about …